Currently, the efforts of state authorities in the fields of pharmaceuticals and healthcare are also aimed at implementing the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030 (hereinafter referred to as the “Pharma 2030 Strategy”). One of the goals of the Pharma 2030 Strategy is to increase the share of domestically produced medicinal products in the total consumption volume from 61.8% to 66.6% by 2030. In this regard, measures to support Russian medicinal products manufacturers continue to be implemented.

On August 7, 2025, a draft law “On Amending the Federal Law ‘On Protection of Competition’” (hereinafter, the “Draft Law”) was published. Prepared by the Federal Antimonopoly Service (hereinafter, the “FAS”), it aims to significantly narrow the scope of antitrust immunities concerning the results of intellectual activity.

On 1 September 2025, a draft resolution of the Government of the Russian Federation “On approving the procedure and criteria for compiling a list of strategically significant medicines” (“Draft Resolution”) was submitted for public discussion.

On August 11, 2025, amendments to the Labor Code of the Russian Federation (hereinafter referred to as the "LC of the RF") entered into force. These amendments concern the provision of guarantees to part-time employees upon termination of an employment contract with them at their primary place of work due to the liquidation of the organization or redundancy or staff cuts at the organization.

On 7 July 2025, Federal Law No. 214-FL «On Amendments to Part Four of the Civil Code of the Russian Federation» was published. This law introduces the following significant changes to the provisions on the recovery of compensation for infringement of exclusive rights to intellectual property and means of individualisation equivalent thereto.

On 14 July 2025, the Council of the State Duma began reviewing Draft Law No. 951518-8 “On Amendments to Article 12 of the Federal Law ‘On Personal Data’” (hereinafter referred to as the “Draft Law”).

On 7 July 2025, the President of the Russian Federation has signed the Federal Law No. 186-FZ of 07.07.2025 “On Amendments to Article 21 of the Federal Law “On Limited Liability Companies" (hereinafter the “Law”), which provides for amendments to the Federal Law No. 14-FZ of 08.02.1998 “On Limited Liability Companies” (hereinafter the “LLC Law”) taking effect on 1 September 2025 regarding the possibility of excluding the pre-emptive right to purchase a share or a part thereof.

On 7 July 2025, the President of the Russian Federation has signed the Federal Law No. 186-FZ of 07.07.2025 “On Amendments to Article 21 of the Federal Law “On Limited Liability Companies" (hereinafter the “Law”), which provides for amendments to the Federal Law No. 14-FZ of 08.02.1998 “On Limited Liability Companies” (hereinafter the “LLC Law”) taking effect on 1 September 2025 regarding the possibility of excluding the pre-emptive right to purchase a share or a part thereof.

On July 11, 2025, a joint letter from the FAS and the Ministry of Health № ТН/61566/25, № 25-7/И/2-13136 dated July 2, 2025 (hereinafter referred to as the "Joint Letter") was published, clarifying the procedure for determining the initial (maximum) contract price (IMCP) in the procurement of pharmaceuticals.